Performance of United States Serologic Assays in the Diagnosis of Lyme Borreliosis Acquired in Europe | Zendy

John A. Branda | Zendy; Franc Strle | Zendy; Klemen Strle | Zendy; Nikhil Sikand | Zendy; Mary Jane Ferraro | Zendy; Allen C. Steere | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Performance of United States Serologic Assays in the Diagnosis of Lyme Borreliosis Acquired in Europe

Author(s) -

John A. Branda,

Franc Strle,

Klemen Strle,

Nikhil Sikand,

Mary Jane Ferraro,

Allen C. Steere

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit235

Subject(s) - medicine , serology , lyme disease , lyme borreliosis , european union , immunology , european standard , gold standard (test) , virology , borrelia burgdorferi , antibody , architectural engineering , business , engineering , economic policy

Physicians in the United States sometimes need to evaluate a patient for suspected Lyme borreliosis (LB) who may have acquired the infection in Europe. Using serum samples from European LB patients, we compared the performance of European and US serodiagnostic tests, including newer-generation assays containing Vmp-like sequence, expressed or its C6 peptide.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research